Metrics appoints a new vice-president to manage and expand its fee-for-service operations.

CMC Biologics and OnoSynergy form an agreement from cell-line development.

Bristol-Myers Squibb agrees to sell global diabetes business to AstraZeneca for $2.7 billion upfront plus an addition $1.4 billion in potential regulatory- and sales-based milestone payments.

Pfizer appoints management changes to take effect in 2014.

Merck Serono, the biopharmaceutical division of Merck, has entered into an agreement on cancer drug development with the Spanish National Cancer Research Centre (CNIO) in Madrid.

AstraZeneca issues a statement regarding the launch of esomeprazole strontium in the United States.

FDA and EMA launch initiative to share bioequivalence inspection information.

Biogen and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, advance plans for anti-TNF biosimilar product candidates.

Bridgepoint Development Capital acquires Quotient for an undisclosed sum.

Accelrys aquires Ireland-based Qumas, a provider of cloud-based and on-premises enterprise compliance software.

Merck's new facility for aseptic production in Reinbek, Germany is scheduled to be completed in 2016.

AstraZeneca's MedImmune will collaborate with Johns Hopkins University in both biologics and small-molecule projects.

Roche announces changes to its board of directors scheduled for March 4, 2014.

FDA has issued a proposed rule to require manufacturers of antibacterial hand soaps and body washes to demonstrate that their products are safe for long-term daily use and more effective than plain soap and water.

Agency issues precautionary recall due to manufacturing fault.

Almost 400 new medicines for infectious diseases, including viral infections, bacterial infections, fungal infections and parasitic infections.

Agency issues precautionary recall due to manufacturing fault.

Charles River Laboratories makes organizational changes to improve the company's productivity initiatives.

Moberg Pharma will acquire three OTC brands from Bayer HealthCare.

GSK forms the Oncology Clinical and Translational Consortium, a scientific research network comprised of six international cancer centers.

Phillips-Medisize announces the expansion to its Kontiolahti, Finland site.

BioWa and Lonza have entered into a licensing agreement with MedImmune for cell line technology.

GlaxoSmithKline plans to expand its facilities in Ware and Worthing in the United Kingdom and will build a new facility for manufacturing innovation.

The University of Missouri's Department of Biochemistry and ABC Laboratories announce industry internship program.

FDA details efforts to evaluate potential risks from use of nanomaterials in drug products and discuss analytical considerations, impact on stability, safety, and toxicology effects.

Roche and Prothena sign deal worth up to $600 million to develop and commercialize antibodies that target alpha-synuclein.

Harlan announces Hiroharu Okochi as president of Harlan Japan.

Johnson&Johnson will open a network of partnering offices across the UK.